Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Mark A. Agius"'
Autor:
Regina Berkovich, Mark A. Agius
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 7 (2014)
Acute and subacute inflammation, the mechanisms by which demyelination and axonal loss occur in multiple sclerosis (MS), result from the migration of activated immune cells into the central nervous system parenchyma. The triggering antigen is unknown
Externí odkaz:
https://doaj.org/article/7ba8534317a14f219c2ce8323a9bc728
Autor:
Adam Cuker, Christopher LaGanke, Congor Nadj, Alexandre Guerreiro, Sven G. Meuth, Brian Steingo, Bart Van Wijmeersch, Karthinathan Thangavelu, Mark A Agius, Krzysztof Selmaj, Timothy Thoits, Claudio E Rodriguez, David Margolin, Ann Jannsens, Tjalf Ziemssen, Darren P Baker, Ann D Bass
Publikováno v:
Multiple Sclerosis (Houndmills, Basingstoke, England)
Background: Alemtuzumab is a highly effective therapy for relapsing-remitting multiple sclerosis (RRMS), and immune thrombocytopenia (ITP) has been identified as a risk. Objective: To examine ITP incidence, treatment, and outcomes during the clinical
Autor:
Jennifer Graves, Adrian Pace, Maria Pia Sormani, Devon S. Conway, Bianca Weinstock-Guttman, Frederick E. Munschauer, Corey C. Ford, Vernon Rowe, Jana Lizrova Preiningerova, Shiv Saidha, Radek Ampapa, Jens Kuhle, Harold L. Moses, Claire S Riley, Tobias Derfuss, Lilyana Amezcua, Joshua Barton, Kottil Rammohan, Pierre Duquette, Thomas Leist, Alexander Rae-Grant, Evanthia Bernitsas, Myla D. Goldman, R. Talab, Jerry S. Wolinsky, Nina De Klippel, Guillermo Izquierdo Ayuso, Bridget Bagert, Virginia Devonshire, Mariko Kita, Hayrettin Tumani, Bhatia Perminder, Scott D. Newsome, Paul S. Giacomini, Frédéric Sedel, Jan Lycke, M. S. Freedman, Stewart Webb, Sanjay Yathiraj, Agata Klosek, Stephen Krieger, Edward Fox, Malgorzata Zajda, Eva Meluzinova, Valerie J Block, Lluís Ramió-Torrentà, John R. Corboy, Aaron E. Miller, Xavier Montalban, Mark A. Agius, Michelle L Apperson, Patricia K. Coyle, Giancarlo Comi, Jose Enrique Martinez Rodriguez, Daniela Rau, Derrick Robertson, Elias Hamp Birte, Douglas L. Arnold, Fred D. Lublin, Galina Vorobeychik, Benjamin Greenberg, Mathias Buttmann, Daniel Bandari, Ludivine Witkowski, Sharon G. Lynch, Victoria Fernandez Sanchez, Jonathan Calkwood, Maria Satori, Tania Kuempfel, Rana K. Zabad, J. Marc Girard, Bruce A.C. Cree, Ahmed T. Toosy, Don J. Mahad, Bruce A. Cohen, Jozef Koscielniak, Jonathan Carter, Daniel Selchen, Paul Friedemann, Sharon Stoll, Fryze Waldemar, Gerd Reifschneider, Mark S. Freedman, Gary Cutter, Franz Fazekas, Robert T. Naismith, Marta Vachova, Richard MacDonell, Mary Ann Picone, Gavin Giovannoni, Randall Trudell, Barbara Willekens, Orhan Aktas, Mark Marriott, Roger McKelvey, Bruce C.A. Cree, Christopher Severson, Rafael Arroyo Gonzalez, Kyle Smoot, Murat Terzi, Joanna Cooper, Lou Brundin, Hans-Peter Hartung, Piotr Sokolowski, Joe Guadagno, Stephen C. Reingold, Klaus Schmierer, Guy Laureys, Robert P. Lisak, Lawrence Samkoff, Carlo Pozzilli, Celia Oreja Guevara, Mitchel Freedman, Anthony T. Reder
Publikováno v:
The lancet neurology
Background: There is an unmet need to develop therapeutic interventions directed at the neurodegeneration that underlies progression in multiple sclerosis. High-dose, pharmaceutical-grade biotin (MD1003) might enhance neuronal and oligodendrocyte ene
Autor:
Neetu Agashivala, Ron Hashmonay, Mark Cascione, Mark S. Freedman, Lawrence P. Goldstick, Mark A. Agius, Kevin McCague, Lesley Schofield, Daniel Kantor, Bruce Hughes, Luigi Barbato, Mark Gudesblatt
Publikováno v:
Multiple Sclerosis and Related Disorders. 3:620-628
Background In pivotal phase 3 studies, fingolimod treatment initiation was associated with a transient reduction in heart rate (HR). Atrioventricular (AV) conduction delays, which were typically asymptomatic, were detected in a small minority of pati
Autor:
Alexander Friend, Eswari Gudipati, Vu B. Trinh, David P. Richman, Stuart W. Morell, Nelson A. Page, Mark A. Agius, Robert H. Fairclough
Publikováno v:
Molecular Immunology. 58:116-131
To develop antigen-specific immunotherapies for autoimmune diseases, knowledge of the molecular structure of targeted immunological hotspots will guide the production of reagents to inhibit and halt production of antigen specific attack agents. To th
Autor:
Glen C. Jickling, Michelle L Apperson, Bradley P. Ander, Boryana Stamova, Mark A. Agius, Frank R. Sharp, Yingfang Tian
Publikováno v:
Journal of Neuroimmunology. 257:90-96
Using two microarray platforms, we identify HLA-DRB5 as the most highly expressed gene in MS compared to healthy subjects. As expected, HLA-DRB5 expression was associated with the HLA-DRB1*1501 MS susceptibility allele. Besides HLA-DRB5, there were 1
Autor:
Michael J. Ferns, David P. Richman, Mark A. Agius, Ricardo A. Maselli, Kayoko Nishi, Peter Pytel, Joachim B. Schnier
Publikováno v:
Annals of the New York Academy of Sciences. 1274:140-147
Antimuscle-specific kinase (anti-MuSK) myasthenia (AMM) differs from antiacetylcholine receptor myasthenia gravis in exhibiting more focal muscle involvement (neck, shoulder, facial, and bulbar muscles) with wasting of the involved, primarily axial,
Autor:
Mark A. Agius, Johan A. Aarli, John Newsom-Davis, Henry J. Kaminski, Nils Erik Gilhus, Angela Vincent, Åse Mygland, Francesco Zorzato
Background: About 50% of patients with thymoma have paraneoplastic myasthenia gravis (MG). Myositis and myocarditis or neuromyotonia (NMT) will also develop in some. Patients with thymoma-associated MG produce autoantibodies to a variety of neuromusc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b174d26454d7d8b1e33d9c566272026d
https://doi.org/10.1001/archneur.57.4.527
https://doi.org/10.1001/archneur.57.4.527
Autor:
Robert J. Fox, Michelle McGovern, Maxine Koepp, Thomai Skaramagas, Michael K. Racke, Vijayshree Yadav, Merit Cudkowicz, Silvia Delgado, Jeffrey D. Long, Augusto Miravalle, Jai Perumal, Myla D. Goldman, Mark A. Agius, Akshata Ashokkumar, Eric C. Klawiter, Robert A. Bermel, Angela Flores, Dixie Ecklund, Patricia K. Coyle, Andrew D. Goodman, Daniel Ontaneda, Kazuko Matsuda, Srividya Ramachandran, Trevis Gleason, Bianca Weinstock-Gutman, Robin Conwit, Valerie Suski, Claire S Riley, Aram Zabeti, Harold L. Moses, Christopher Severson, Dana Dewitt, Brenda Thornell, Shlomo Shinnar, Khurram Bashir, Neil Lava, Jon W. Yankey, Robert T. Naismith, Pavle Repovic, Sneha Natarajan, Bruce A. Cohen, Sharon G. Lynch, Barbara Giesser, Christopher S. Coffey, Burk Jubelt
Publikováno v:
Contemporary clinical trials. 50
Background Primary and secondary progressive multiple sclerosis (MS), collectively called progressive multiple sclerosis (PMS), is characterized by gradual progression of disability. The current anti-inflammatory treatments for MS have little or no e
Autor:
Michelle L Apperson, Heather Rose, Mark A. Agius, Kimberly A. Hardin, Robert A. Dias, Steven D. Brass
Publikováno v:
Sleep and Breathing. 16:1255-1265
This study aims: (1) to identify patients with multiple sclerosis (MS) who are at high risk for obstructive sleep apnea (OSA) by utilizing the STOP-BANG questionnaire and (2) to evaluate the relationship between OSA risk as determined by the STOP-BAN